Postmenopausal Osteoporosis Treatments
Find Postmenopausal Osteoporosis Treatments
Medications for Postmenopausal Osteoporosis
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Postmenopausal Osteoporosis.
Found 11 Approved Drugs for Postmenopausal Osteoporosis
Denosumab
Brand Names
Aukelso, Bildyos, Bilprevda, Bomyntra, Boncresa, Bosaya, Conexxence, Denosumab-BMWO, ENOBY, Jubbonti, Osenvelt, Ospomyv, Oziltus, Stoboclo, WYOST, Xgeva, Xtrenbo
Denosumab
Brand Names
Aukelso, Bildyos, Bilprevda, Bomyntra, Boncresa, Bosaya, Conexxence, Denosumab-BMWO, ENOBY, Jubbonti, Osenvelt, Ospomyv, Oziltus, Stoboclo, WYOST, Xgeva, Xtrenbo
Form: Injection
Method of administration: Subcutaneous
FDA approval date: June 05, 2010
Classification: RANK Ligand Inhibitor
Aukelso is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.
Alendronate
Brand Names
Binosto, Fosamax
Alendronate
Brand Names
Binosto, Fosamax
Form: Tablet, Solution
Method of administration: Oral
FDA approval date: February 06, 2008
Classification: Bisphosphonate
BINOSTO is a bisphosphonate indicated for: Treatment of osteoporosis in postmenopausal women.
Teriparatide
Brand Names
Bonsity, Forteo
Teriparatide
Brand Names
Bonsity, Forteo
Form: Injection
Method of administration: Subcutaneous
FDA approval date: November 26, 2002
Classification: Parathyroid Hormone Analog
BONSITY is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, BONSITY reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. BONSITY is a parathyroid hormone analog, (PTH 1-34), indicated for: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 )
Showing 1-5 of 11
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances